Verastem AI Stock Analysis
Want to see VSTM full AI Analyst Report?
Verastem (VSTM) AI Stock Analysis
Verastem
(NASDAQ:VSTM)
The score is held back primarily by weak financial performance: large ongoing losses, heavy and worsening cash burn, and a highly levered balance sheet. Offsetting this, the latest earnings call conveyed strong commercial growth and a well-defined clinical/regulatory roadmap with funding runway into 1H 2028. Technically, the setup is mixed (positive longer-term trend vs. weaker near-term momentum), and valuation remains hard to anchor due to negative earnings and no dividend yield data.
Verastem (VSTM) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $865.72M
- Dividend Yield
- ―
- Average Volume (3M)
- 3.47M
- Price to Earnings (P/E)
- -3.7
- Beta (1Y)
- 1.16
- Revenue Growth
- 649.65%
- EPS Growth
- 54.01%
- Country
- US
- Employees
- 102
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Verastem Business Overview & Revenue Model
Company Description
Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by...
Verastem Earnings Call Summary
The call was strongly positive overall. Management reported 114% year-over-year product revenue growth, increasing refill momentum, a strengthened balance sheet with funding into the first half of 2028, encouraging VS-7375 efficacy across pancreatic, colorectal and lung cancers, favorable safety data, and multiple advancing Phase II and Phase III programs. The main negatives were moderated new patient starts, anticipated competitive pressure in pancreatic cancer, a larger adjusted net loss, and remaining clinical, regulatory and site-enrollment execution requirements.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Verastem expects SG&A expenses will remain consistent on a quarterly basis in the fourth quarter of 2026, with current cash, October follow-on offering proceeds and expected AVMAPKI FAKZYNJA CO-PACK revenues funding operations into the first half of 2028, including completing VS-7375 Phase II studies and starting 3 pivotal Phase III studies; pancreatic and colorectal Phase II enrollment is expected to complete around the end of the year and lung enrollment in the first half of 2027, the frontline Phase III TARGET-D 301 PDAC trial is expected to initiate before the end of 2026, and the frontline Phase III TARGET-D trials in CRC and non-small cell lung cancer are planned for the first half of 2027. The company expects an update across the program at the first of the year, multiple updates across the program in the next couple of months, the blister pack to launch in the first half of next year, 7375 plus gem/nab data in Q1 or Early Q2, and typically these Phase IIIs are 100 sites.
Verastem Financial Statement Overview
Summary
Revenue is scaling rapidly (TTM ~$100.3M vs. $30.9M in 2025), but profitability and cash generation remain very weak (TTM net income about -$178.9M; operating cash flow about -$159.6M; free cash flow about -$160.9M). Balance-sheet risk is elevated given sharply higher leverage (TTM debt ~$122.1M vs. equity ~$10.1M; ~12.1x debt-to-equity), implying continued funding pressure despite the revenue ramp.
Income Statement
22NegativeBalance Sheet
28NegativeCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 100.30M | 30.91M | 10.00M | 0 | 2.60M | 2.05M |
| Gross Profit | 86.37M | 25.62M | 10.00M | 0 | 2.60M | 2.05M |
| EBITDA | -175.58M | -207.60M | -125.86M | -83.17M | -71.56M | -61.16M |
| Net Income | -178.90M | -209.47M | -130.64M | -87.37M | -73.81M | -71.20M |
Balance Sheet | ||||||
| Total Assets | 229.64M | 246.44M | 101.54M | 149.72M | 95.05M | 108.66M |
| Cash, Cash Equivalents and Short-Term Investments | 172.80M | 204.99M | 88.82M | 137.13M | 87.89M | 100.26M |
| Total Debt | 122.12M | 76.86M | 42.25M | 41.56M | 27.07M | 3.18M |
| Total Liabilities | 219.54M | 189.25M | 130.43M | 92.34M | 47.66M | 21.10M |
| Stockholders Equity | 10.10M | 57.20M | -28.89M | 57.37M | 47.39M | 87.56M |
Cash Flow | ||||||
| Free Cash Flow | -160.92M | -137.51M | -104.80M | -86.46M | -63.67M | -53.70M |
| Operating Cash Flow | -159.57M | -137.51M | -104.77M | -86.46M | -63.67M | -53.50M |
| Investing Cash Flow | -8.61M | -9.62M | 59.97M | -44.45M | 66.19M | 87.00K |
| Financing Cash Flow | 203.28M | 263.31M | 54.78M | 134.19M | 51.78M | 6.88M |
Verastem Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VSTM, the sentiment is Negative. The current price of 6.87 is below the 20-day moving average (MA) of 9.08, below the 50-day MA of 8.44, and above the 200-day MA of 6.31, indicating a neutral trend. The MACD of -0.30 indicates Positive momentum. The RSI at 31.19 is Neutral, neither overbought nor oversold. The STOCH value of 2.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VSTM.
Verastem Risk Analysis
Verastem disclosed 67 risk factors in its most recent earnings report. Verastem reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksVerastem Peers Comparison
Overall Rating
PBYI61Neutral
VSTM54Neutral
ARVN49Neutral
CTMX46Neutral
ALLO40Underperform
BBOT37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 61Neutral | $369.13M | 15.16 | 17.52% | ― | 9.35% | -37.15% | |
| 54Neutral | $865.72M | -3.71 | -359.49% | ― | 649.65% | 54.01% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | $443.01M | -45.10 | -2.00% | ― | -11.85% | 81.44% | |
| 46Neutral | $409.85M | -4.17 | -33.97% | ― | -87.66% | -210.45% | |
| 40Underperform | $241.11M | -1.10 | -49.84% | ― | ― | 36.37% | |
| 37Underperform | $144.85M | -0.00 | -49.01% | ― | ― | -132725.78% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| VSTM | Verastem Inc | 6.87 | -3.13 | -31.30% | |
| PBYI | Puma Biotechnology | 7.22 | 2.33 | 47.65% | |
| CTMX | CytomX Therapeutics Inc. | 1.88 | -2.00 | -51.55% | |
| ARVN | Arvinas Holding Company | 6.76 | -4.75 | -41.28% | |
| ALLO | Allogene Therapeutics | 0.69 | -0.54 | -43.50% | |
| BBOT | Bridgebio Oncology Therapeutics, Inc. | 1.80 | -10.59 | -85.43% |
Verastem Corporate Events
Verastem Updates Corporate Presentation on Oncology Programs
NeutralOn November 5, 2026, Verastem posted an updated corporate presentation on its website. The presentation covered the company’s oncology programs and product candidates, including AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules and defactinib tablets)...
Verastem Announces $234 Million Oncology Financing Transaction
PositiveOn October 14, 2026, Verastem entered into an underwriting agreement with Jefferies and Guggenheim Securities for an underwritten public offering of 30,937,500 shares of common stock and pre-funded warrants to purchase up to 312,503 additional shares...
Verastem Oncology Announces CEO Transition to Michael Bailey
PositiveVerastem Oncology said on October 14, 2026, that longtime executive Daniel Paterson will retire as president and CEO effective January 1, 2027, while remaining on the board and serving as an advisor, with board member and veteran oncology executive M...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026
